Foghorn Therapeutics, Inc. (FHTX)
1.905
-0.20
(-9.29%)
USD |
NASDAQ |
Nov 05, 16:00
1.905
0.00 (0.00%)
After-Hours: 20:00
Foghorn Therapeutics SG&A Expense (TTM) : 26.38M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 26.38M |
| March 31, 2026 | 26.89M |
| December 31, 2025 | 27.55M |
| September 30, 2025 | 27.11M |
| June 30, 2025 | 27.42M |
| March 31, 2025 | 27.89M |
| December 31, 2024 | 28.36M |
| September 30, 2024 | 29.03M |
| June 30, 2024 | 30.36M |
| March 31, 2024 | 31.44M |
| December 31, 2023 | 32.37M |
| September 30, 2023 | 33.21M |
| June 30, 2023 | 32.87M |
| Date | Value |
|---|---|
| March 31, 2023 | 32.17M |
| December 31, 2022 | 30.75M |
| September 30, 2022 | 29.22M |
| June 30, 2022 | 27.06M |
| March 31, 2022 | 24.25M |
| December 31, 2021 | 21.73M |
| September 30, 2021 | 19.96M |
| June 30, 2021 | 16.70M |
| March 31, 2021 | 13.72M |
| December 31, 2020 | 11.25M |
| September 30, 2020 | 6.687M |
| June 30, 2020 | 4.132M |
| March 31, 2020 | 2.221M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Anavex Life Sciences Corp. | 5.935M |
| Vaxcyte, Inc. | 100.22M |
| Connect Biopharma Holdings Ltd. | 13.09M |
| Caribou Biosciences, Inc. | 33.74M |
| Arrowhead Pharmaceuticals, Inc. | 172.57M |